Revolution Medicines (RVMD) Operating Expenses (2019 - 2026)

Revolution Medicines' Operating Expenses history runs 8 years deep, the most recent figure standing at $445.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 84.92% year-over-year to $445.2 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 75.68% YoY), while the FY2025 annual figure was $1.2 billion, up 71.48% from the prior year.
• Operating Expenses was $445.2 million for Q1 2026 at Revolution Medicines, up from $361.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $445.2 million in Q1 2026 to a low of $65.5 million in Q1 2022.
• Historically, Operating Expenses has averaged $182.9 million across 5 years, with a median of $156.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 134.6% in 2023, then rose 19.69% in 2024.
• A 5-year view of Operating Expenses shows it stood at $77.0 million in 2022, then surged by 134.6% to $180.7 million in 2023, then increased by 19.69% to $216.3 million in 2024, then jumped by 67.18% to $361.6 million in 2025, then grew by 23.12% to $445.2 million in 2026.
• The last three Operating Expenses figures came in at $445.2 million (Q1 2026), $361.6 million (Q4 2025), and $315.3 million (Q3 2025), per Business Quant data.